DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Otilimab
Otilimab
(COVID-19) in the Era of Cardiac Vigilance: a Systematic Review
Q3 2020 Results
Q3 2019 Results
Inflammatory Response in Children & Adults
Immunomodulators Under Evaluation for the Treatment of COVID-19
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Bispecific T-Cell Redirection Versus Chimeric Antigen Receptor (CAR)-T Cells As Approaches to Kill Cancer Cells
Cellular Immunology the Role of B Cells in Multiple Sclerosis
Overview of Planned Or Ongoing Studies of Drugs for the Treatment of COVID-19
MRI of the Joint and Evaluation of the Granulocyte–Macrophage Colony
GSK Announces Results Evaluating Its Investigational Monoclonal Antibody, Otilimab, for the Treatment of Hospitalised Adult Patients with COVID-19
Beyond Counting Sheep: New Strategies for Sleep Maintenance Insomnia
Therapies for Multiple Sclerosis Targeting B Cells 89
A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR)
205180 RENAISSANCE Ms.Pdf
Stembook 2018.Pdf
Glaxo Fails to Win an Oscar
The Signal Pathways and Treatment of Cytokine Storm in COVID-19
Top View
Interim Clinical Guidance for Adults with Suspected Or Confirmed Covid-19 in Belgium
Nucleic Acid-Based Approaches for Tumor Therapy
PDF of Antibody News
The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin-6 Signaling in COVID-19- Related Systemic Inflammatory Response
Managing the Covid-19 Pandemic: Therapeutics Are As Important As Vaccines
GM-CSF: a Promising Target in Inflammation and Autoimmunity
Journal for Immunotherapy of Cancer (JITC) Preprint
1 Pathophysiology of Acute Respiratory Syndrome
Gilead to File Filgotinib for RA in 2019, Earlier Than Forecast
University of Birmingham Efficacy, Patient-Reported Outcomes, And
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
Q2 2020 Results Slides
Rxoutlook® 3Rd Quarter 2021
GM-CSF-Based Treatments in COVID-19: Reconciling Opposing Therapeutic Approaches
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Winter 2021 Pharmacy Market Outlook 2 Table of Contents
The Role of GM-CSF Posted July 30, 2020
New Breakthrough in the Treatment of Rheumatoid Arthritis 25 November 2020
Clinical Trials Summary Our R&D Pipeline 20 Vaccines and 42 Medicines in 77 Different Programs
Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
Antibodies[Version 1; Peer Review: 2 Approved]
Efficacy of Pharmacological Treatment in Rheumatoid Arthritis
PDCO Agenda of the 20-23 July 2021 Meeting
The Big Covid-19 Trials Still to Report
Download PDF File
Paediatric Committee (PDCO) Minutes for the Meeting on 26-29 May 2020
Namilumab Or Infliximab Compared to Standard of Care in Hospitalised Patients with COVID-19 (CATALYST): a Phase 2 Randomised Adaptive Trial
PDCO May Monthly Report
Efficacy of Pharmacological Treatment in Rheumatoid Arthritis